{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:45Z","timestamp":1790456085384,"version":"4.1.0"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prevalence and burden of diabetes are on the rise in India, making it \u2018the diabetes capital of the world\u2019. Comorbidities such as obesity, cardiovascular (CV) complications, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), and neurodegenerative diseases are common in patients with diabetes. Recent breakthroughs in diabetes medications and continuous glucose monitoring have resulted in a paradigm shift in diabetes care. Hence, a review in the Indian context is warranted. This review focuses on the existing evidence (gathered by a systematic literature search utilising online databases such as PubMed) on the metabolic, cardio-renoprotective, and hepatoprotective effects of sodium-glucose co-transporter 2 (SGLT2) inhibition, particularly in the Indian setting. The study revealed that the SGLT2 inhibitors (SGLT2i), with their numerous pleiotropic benefits, have received considerable attention recently as a novel class of antihyperglycaemic agents (AHAs) for the management of diabetes. SGLT2i play a crucial role in the transition from glycaemic control to metabolic care, particularly in the context of obesity, CV disease and renal disease. In addition to improving glycaemic control, SGLT2i have been shown to promote weight loss, reduce blood pressure and improve lipid profiles, which are key components of metabolic health. Moreover, SGLT2i have demonstrated renal protective effects, including a reduction in albuminuria and a slower decline in the estimated glomerular filtration rate (eGFR), suggesting a potential role in the management of renal dysfunction.<\/jats:p>","DOI":"10.4103\/ijem.ijem_377_23","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T02:00:15Z","timestamp":1709085615000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care\u2014An Indian Perspective"],"prefix":"10.4103","volume":"28","author":[{"given":"K M Prasanna","family":"Kumar","sequence":"first","affiliation":[{"name":"Centre for Diabetes and Endocrine Care and Diabetes Care, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G","family":"Unnikrishnan","sequence":"additional","affiliation":[{"name":"Chellaram Diabetes Institute, Bavdhan, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Jariwala","sequence":"additional","affiliation":[{"name":"Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Mehta","sequence":"additional","affiliation":[{"name":"Sir Ganga Ram Hospital, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Indraprastha Apollo Hospital, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Panchal","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson Private Limited, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet","family":"Lakhani","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson Private Limited, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Acharya","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson Private Limited, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Dixit","sequence":"additional","affiliation":[{"name":"Evidence Generation Centre and Strategic Alliances, Janssen Inc., Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.4103\/ijo.IJO_1627_21","article-title":"Epidemiology of type 2 diabetes in India","volume":"69","author":"Pradeepa","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019:A systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"R4-20240828","first-page":"113","article-title":"Cardiorenal syndrome in type 2 diabetes mellitus-Rational use of sodium-glucose cotransporter-2 inhibitors","volume":"16","author":"Kalra","year":"2020","journal-title":"Eur Endocrinol"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s40200-021-00834-y","article-title":"Trends in the diabetes incidence and mortality in India from 1990 to 2019: A joinpoint and age-period-cohort analysis","volume":"20","author":"Jha","year":"2021","journal-title":"J Diabetes Metab Disord"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India:The ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12916-019-1373-y","article-title":"The comorbidity burden of type 2 diabetes mellitus:Patterns, clusters and predictions from a large English primary care cohort","volume":"17","author":"Nowakowska","year":"2019","journal-title":"BMC Med"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S2213-8587(22)00072-9","article-title":"Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13):A national cross-sectional study","volume":"10","author":"Anjana","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(1 Suppl)","key":"R9-20240828","first-page":"12","article-title":"Current glycemic status and diabetes related complications among type 2 diabetes patients in India:Data from the A1chieve study","volume":"61","author":"Mohan","year":"2013","journal-title":"J Assoc Physicians India"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.7861\/clinmed.2021-0370","article-title":"Managing obesity in people with type 2 diabetes","volume":"21","author":"Grant","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DMSO.S51325","article-title":"Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies:A systematic literature review","volume":"6","author":"Colosia","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"e0263619","DOI":"10.1371\/journal.pone.0263619","article-title":"Cardiovascular risk in newly diagnosed type 2 diabetes patients in India","volume":"17","author":"Unnikrishnan","year":"2022","journal-title":"PLoS One"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0972753121998496","article-title":"Cost of management of diabetes mellitus:A pan India study","volume":"27","author":"Nagarathna","year":"2020","journal-title":"Ann Neurosci"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.diabres.2010.05.009","article-title":"The socioeconomics of diabetes from a developing country:A population based cost of illness study","volume":"89","author":"Tharkar","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"R15-20240828","first-page":"473","article-title":"Economic analysis of diabetes care","volume":"125","author":"Kapur","year":"2007","journal-title":"Indian J Med Res"},{"key":"R16-20240828","first-page":"1418","article-title":"Metabesity:Expert panel recommendation for taking up the challenge by a multidisciplinary approach","volume":"70","author":"Raza","year":"2020","journal-title":"J Pak Med Assoc"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes:Basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor:Current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/kidneydial2020032","article-title":"The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1","volume":"2","author":"Oe","year":"2022","journal-title":"Kidney Dial"},{"issue":"Suppl 2(Suppl 2)","key":"R22-20240828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13630","article-title":"What does sodium-glucose co-transporter 1 inhibition add:Prospects for dual inhibition","volume":"21","author":"Dominguez Rieg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s12325-019-01054-w","article-title":"Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes","volume":"36","author":"Handelsman","year":"2019","journal-title":"Adv Ther"},{"issue":"(Suppl 1)","key":"R25-20240828","first-page":"S125","article-title":"9. Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"2020-7","DOI":"10.7573\/dic.2020-7-4","article-title":"Ertugliflozin in the treatment of type 2 diabetes mellitus","volume":"9","author":"Marrs","year":"2020","journal-title":"Drugs Context"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes:A systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/03007995.2017.1391759","article-title":"Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes","volume":"34","author":"Merton","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13340-020-00472-4","article-title":"Remogliflozin:The new low cost SGLT-2 inhibitor for type 2 diabetes mellitus","volume":"12","author":"Atal","year":"2021","journal-title":"Diabetol Int"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14656566.2020.1776262","article-title":"An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes-an Asian perspective","volume":"21","author":"Saisho","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"(Suppl 1)","key":"R32-20240828","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment:Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"R34-20240828","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M20-5938","article-title":"Diabetes management in chronic kidney disease:Synopsis of the 2020 KDIGO clinical practice guideline","volume":"174","author":"Navaneethan","year":"2021","journal-title":"Ann Intern Med"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R39-20240828","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R40-20240828","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2022.03.031","article-title":"Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis:Update on recent mechanistic insights related to kidney physiology","volume":"100","author":"Van Ruiten","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R41-20240828","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R42-20240828","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R43-20240828","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 Inhibitors:A Review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"R44-20240828","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism:Results of a randomized trial","volume":"63","author":"Stein","year":"2014","journal-title":"Metabolism"},{"key":"R45-20240828","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion:Results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"R51-20240828","doi-asserted-by":"crossref","first-page":"745","DOI":"10.14740\/jocmr3112w","article-title":"Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2\/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus","volume":"9","author":"Takebayashi","year":"2017","journal-title":"J Clin Med Res"},{"key":"R52-20240828","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2019.01.029","article-title":"Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus","volume":"149","author":"Koike","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R53-20240828","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12325-021-01984-4","article-title":"Real-world safety and effectiveness of canagliflozin treatment for type 2 diabetes mellitus in Japan:SAPPHIRE, a long-term, large-scale post-marketing surveillance","volume":"39","author":"Inagaki","year":"2022","journal-title":"Adv Ther"},{"key":"R54-20240828","first-page":"11","article-title":"A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the management of patients with type ii diabetes mellitus","volume":"70","author":"Bhosle","year":"2022","journal-title":"J Assoc Physicians India"},{"key":"R55-20240828","first-page":"46","article-title":"Efficacy of SGLT2 Inhibitors as the fifth drug in the management of type 2 diabetes mellitus in Asian Indians not controlled with at least 4 oral antidiabetic drugs","volume":"66","author":"Panikar","year":"2018","journal-title":"J Assoc Physicians India"},{"key":"R56-20240828","first-page":"40","article-title":"A Prospective Analysis of the Efficacy and safety of sodium glucose cotransporter 2 inhibitors:Real world evidence from clinical practice in India","volume":"64","author":"Sosale","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"R57-20240828","first-page":"36","article-title":"Efficacy and safety of canagliflozin in patients with type ii diabetes mellitus inadequately controlled on triple drug therapy","volume":"67","author":"Bhosle","year":"2019","journal-title":"J Assoc Physicians India"},{"key":"R58-20240828","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition:A review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"R59-20240828","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","article-title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","volume":"58","author":"Cefalu","year":"2015","journal-title":"Diabetologia"},{"key":"R60-20240828","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.3390\/jcm9072275","article-title":"Real-world clinical outcomes associated with canagliflozin in patients with type 2 diabetes mellitus in Spain:The Real-Wecan Study","volume":"9","author":"Gorgojo-Mart\u00ednez","year":"2020","journal-title":"J Clin Med"},{"key":"R61-20240828","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5603\/DK.2020.0044","article-title":"Glycaemic and weight-loss outcomes of graded doses of canagliflozin in type 2 diabetes \u2014A real-world study","volume":"9","author":"Dutta","year":"2020","journal-title":"Clin. Diabetol"},{"key":"R62-20240828","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/ijem.IJEM_55_19","article-title":"Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting:COLOR Study","volume":"23","author":"Aneja","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"R63-20240828","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/2230-8210.179996","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India","volume":"20","author":"Prasanna Kumar","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"R65-20240828","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/ehf2.13905","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure:An updated meta-analysis","volume":"9","author":"Cao","year":"2022","journal-title":"ESC Heart Fail"},{"key":"R66-20240828","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ehf2.13805","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction:A meta-analysis","volume":"9","author":"Pandey","year":"2022","journal-title":"ESC Heart Fail"},{"key":"R67-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000503919","article-title":"The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients:A systematic review and meta-analysis","volume":"10","author":"Lo","year":"2020","journal-title":"Cardiorenal Med"},{"key":"R68-20240828","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eprac.2022.05.005","article-title":"Different sodium-glucose cotransporter-2 inhibitors:Can they prevent death?","volume":"28","author":"Mukhopadhyay","year":"2022","journal-title":"Endocr Pract"},{"key":"R69-20240828","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R70-20240828","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00392-021-01913-z","article-title":"Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure:A systematic review and head-to-head comparative efficacy network meta-analysis","volume":"111","author":"T\u00e4ger","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"R71-20240828","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12933-019-0869-2","article-title":"The CANVAS Program:Implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus","volume":"18","author":"Carbone","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R74-20240828","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"R75-20240828","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic Kidney Disease and SGLT2 Inhibitors:A Review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv Ther"},{"key":"R76-20240828","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"R77-20240828","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.3390\/ijms24108732","article-title":"SGLT2 Inhibitors:A New therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases","volume":"24","author":"Di Costanzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R78-20240828","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jdi.13624","article-title":"Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries:Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"R79-20240828","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s11255-022-03117-4","article-title":"Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus:A network meta-analysis and systematic review","volume":"54","author":"Lin","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"R80-20240828","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD:State of Art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R81-20240828","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4239\/wjd.v10.i2.114","article-title":"SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus:A systematic review","volume":"10","author":"Raj","year":"2019","journal-title":"World J Diabetes"},{"key":"R82-20240828","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3748\/wjg.v28.i26.3243","article-title":"Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis\/fibrosis\/inflammation and redox balance in non-alcoholic fatty liver disease","volume":"28","author":"Bellanti","year":"2022","journal-title":"World J Gastroenterol"},{"key":"R84-20240828","doi-asserted-by":"crossref","first-page":"222","DOI":"10.18433\/jpps29831","article-title":"Effects of Canagliflozin on fatty liver indexes in patients with type 2 diabetes:A meta-analysis of randomized controlled trials","volume":"21","author":"Li","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"R85-20240828","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease:A randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"R86-20240828","doi-asserted-by":"crossref","first-page":"109791","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease:A systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"R87-20240828","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/osp4.294","article-title":"Efficacy of canagliflozin against nonalcoholic fatty liver disease:A prospective cohort study","volume":"4","author":"Itani","year":"2018","journal-title":"Obes Sci Pract"},{"key":"R88-20240828","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus:A 5-year follow-up study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol Commun"},{"key":"R90-20240828","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccl.2021.04.007","article-title":"New antidiabetes medications and their cardiovascular and renal benefits","volume":"39","author":"Ferro","year":"2021","journal-title":"Cardiol Clin"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_377_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:44Z","timestamp":1787768624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_377_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_377_23","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}